BIO News and Press, Bio-Rad Laboratories Inc. Class A From 10/24/23

2023-10-24 22:33:48 ET Summary Bio-Rad Laboratories' investment returns are expected to be hindered by economic and technical factors. The company's large ownership in Sartorius AG has been a hindrance due to the latter's poor performance and high correlations between the pair. ...

2023-10-24 10:21:05 ET More on Danaher Danaher Corporation 2023 Q3 - Results - Earnings Call Presentation Danaher: Short-Term Headwinds, But Long-Term Tailwinds Veralto: Thoughts On The Danaher Spinoff Danaher beats Q3 top-line and bottom-line estimates; init...

2023-10-17 17:37:28 ET More on Bio-Rad Labs Evelo Biosciences enters into termination and surrender pact with Bio-Rad Seeking Alpha’s Quant Rating on Bio-Rad Labs Historical earnings data for Bio-Rad Labs For further details see: Bio-Rad Laboratori...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2023 on Thursday, October 26, 2023, following the close of the market. Management will discuss these results in a...

Bio-Rad Laboratories, Inc. (NYSE: BIO) is one of today's top gainers. The company's shares are currently up 2.25% on the day to $370.1. Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, an...

2023-09-02 07:38:58 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks soared high during the COVID-19 pandemic, as they were our only hope for new drugs and vaccines to fight the virus. However, the biotech sector received little thanks from th...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that the company’s management will participate in a fireside chat event during Wells Fargo’s 2023 Healthcare Conference on Thursday, September ...

2023-08-10 07:03:05 ET Summary We are initiating Bio-Rad with a buy rating and FY23 warranted DCF value of $495. Share prices have fallen over 50% from the peak and are trading at a discount according to systematic DCG valuation and industry averages. BIO's investment in Sarto...

2023-08-06 17:35:15 ET More on the markets Charts Say Pullback Should Be Followed By Higher Highs SPY: It's Time To Book Some Profits (Technical Analysis, Rating Downgrade) 3 Reasons Why SPY Could Be On The Cusp Of A Bear Market Roth MKM still sees recession ...

2023-08-03 23:33:03 ET Bio-Rad Laboratories, Inc. (BIO) Q2 2023 Earnings Conference Call August 3, 2023 17:00 ET Company Participants Edward Chung - Head, Investor Relations Norman Schwartz - Chief Executive Officer Ilan Daskal - Executive Vice President and Chie...